Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

1. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet. 2014;383:524–32. doi: 10.1016/S0140-6736(13)62218-7 24192252

2. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–57. doi: 10.1016/S1470-2045(09)70360-2 20089449

3. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78–88. doi: 10.1016/S1470-2045(11)70296-0 22177579

4. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864–71. doi: 10.1016/j.ejca.2011.01.008 21334200

5. Elfström KM, Smelov V, Johansson AL, Eklund C, Nauclér P, Arnheim-Dahlström L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;348:g130. doi: 10.1136/bmj.g130 24435414

6. Isidean SD, Mayrand MH, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int J Cancer. 2016; 139(11):2456–66. doi: 10.1002/ijc.30385 27538188

7. Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, et al. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017; 140(2):440–448. doi: 10.1002/ijc.30454 27685757

8. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136(2):189–97. doi: 10.1016/j.ygyno.2014.11.076 25579108

9. Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al. Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. J Natl Cancer Inst. 2014; 106(8): dju153. doi: 10.1093/jnci/dju153

10. Brotherton JML, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013;199:614–17. doi: 10.5694/mja13.10272 24182228

11. Brotherton J, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey. Vaccine. 2014;32:592–7. doi: 10.1016/j.vaccine.2013.11.075 24316239

12. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206:1645–51. doi: 10.1093/infdis/jis590 23087430

13. Smith M, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015;211(1):91–9. doi: 10.1093/infdis/jiu370 25117753

14. Australian Institute of Health and Welfare. Cervical screening in Australia 2011–2012. Canberra: Australian Institute of Health and Welfare; 2014 [cited 2017 Aug 15]. Cancer series no. 82. Cat. no. CAN 79. Available from: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129547030.

15. Brotherton J, Gertig DM, May CM, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204(5):184. doi: 10.5694/mja15.01038 26985843

16. National Health and Medical Research Council. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: Commonwealth of Australia; 2005.

17. Medical Services Advisory Committee. National Cervical Screening Program renewal: evidence review. Canberra: Commonwealth of Australia; 2013 [cited 2017 Aug 15]. MSAC application no. 1276. Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/E6A211A6FFC29E2CCA257CED007FB678/$File/Review%20of%20Evidence%20notated%2013.06.14.pdf.

18. Lew JB, Simms K, Smith M, Hall M, Kang YJ, Xu X, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96–107. doi: 10.1016/S2468-2667(17)30007-5

19. Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017; 144(1):51–56. doi: 10.1016/j.ygyno.2016.10.031 28094038

20. Victorian Cervical Cytology Registry. Statistical report 2013. Carlton: Victorian Cervical Cytology Registry; 2013 [cited 2017 Aug 15]. Available from: http://www.vccr.org/site/VCCR/filesystem/documents/dataandresearch/StatisticalReports/VCS_StatisticsReport_2013_Web_SinglePages_Final.pdf.

21. Australian Institute of Health and Welfare. Cervical screening in Australia 2012–2013. Canberra: Australian Institute of Health and Welfare; 2015 [cited 2017 Aug 15]. Cancer series no. 93. Cat. no. CAN 91. Available from: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129550872.

22. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99. doi: 10.1016/j.vaccine.2012.06.095 23199969

23. Canfell K. The Australian example: an integrated approach to HPV vaccination and cervical screening. HPV Today. 2015;34:17–22. Available from: http://usinfo.roche.com/rs/975-FPO-828/images/HPV-Today-Article_PP-US-05575.pdf.

24. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46e1–11. doi: 10.1016/j.ajog.2011.07.024 21944226

25. Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia; 2017 [cited 2017 Aug 15]. Available from: http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.

26. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med. 2011;9:104. doi: 10.1186/1741-7015-9-104 21910918

27. Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, et al. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Serv Res. 2016;16:147. doi: 10.1186/s12913-016-1375-9 27112193